Table 5 Comparison of the clinical and immunological characteristics according to the genotype of F2RL1 c.621C/T

Age (y) (median [IQR])

39 (30–53)

34.5 (19.5–43.7)

Sex-Female (n[%])

44 (64.7%)

2 (25%)

BMI (kg/m2) (median [IQR])

27.9(23.3–31.5)

23.3 (21.3–27.4)

History of smoking (n[%])

24 (35.3%)

1 (12.5%)

FEV₁ (% predicted) (median [IQR])

85.5 (70.2–92.0)

89-(80.2–102.2)

FEV₁/FVC(% predicted) (median [IQR])

82.0 (69–87.7)

83.5(65.5–89.7)

IgE* (kU/L) (median [IQR])

1.73 (1.2–2.2)

1.86 (1.79-)

Eosinophils** (cells/µl)

200 (100–440)

250 (172–705)

Proportion of TH2 cells/WBC^#

0.24 (0.15–0.46)

0.25 (0.08–0.42)

PAR-2 mRNA^##Expression (copies/1000 GAPDH copies)

19.7 (11.15–30.7)

6.0 (2.83–15.7)

Percentage of IMMo expressing PAR-2^&

14.2 (6.03–31.0)

14.50 (7.76–47.27)

Percentage of CMo expressing PAR-2^&&

5.45 (1.37–12.05)

14.95 (5.08–28.07)

CCL5 (ng/ml)^¶

50.95 (36.59–78.15)

41.53 (24.14–52.73)

PGD2 (pg/ml)^∞

346.93 (130.7–769.38)

492.54 (148.57–1809.07)

IL-13 (pg/ml)^€

3.52 (1.0–33.39)

8.67 (1.32–43.75)